GOTU penny stock potential

What happened: On March 19, Truist initiated coverage of Altimmune Inc. (NASDAQ:ALT) with a $12 price target, indicating a 315% upside potential. ALT is among the 10 most shorted penny stocks. Separately, Gaotu Techedu Inc. (NYSE:GOTU), a consumer staples penny stock, received a Buy rating from 4 out of 6 analysts, with a median 1-year target price of $3. Autolus Therapeutics plc (NASDAQ:AUTL), a biotech penny stock, reported strong Q4 and full-year 2025 results, driving its commercial scale-up of CAR T-cell therapy, AUCATZYL.

Market impact: The positive analyst coverage and strong earnings reports have driven interest in these penny stocks, potentially attracting more retail and institutional investors. This could lead to increased trading volumes and price appreciation, particularly for ALT with its substantial upside potential. The biotech and consumer staples sectors may see further investor interest, given AUTL's and GOTU's promising outlooks.

What to watch next: On May 15, Altimmune Inc. is expected to report Q1 2026 earnings, which could provide updates on its pipeline and validate Truist's bullish stance. Additionally, investors should monitor Autolus Therapeutics' progress towards its 2026 commercialization goals, with a focus on its upcoming data presentations at the American Association for Cancer Research (AACR) Annual Meeting in April 2027. Lastly, any regulatory updates or analyst rating changes for Gaotu Techedu could influence its stock performance.